INDO US BIOTECH
Back to Balance Sheet
|
INDO US BIOTECH Last 5 Year Contingent Liabilities History
[Standalone]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹2.91 Cr | ₹1.17 Cr | ₹0.98 Cr | ₹0.95 Cr | ₹0.67 Cr |
What is the latest Contingent Liabilities ratio of INDO US BIOTECH ?
| Year | Contingent Liabilities |
|---|---|
| Mar2026 | ₹2.91 Cr |
| Mar2025 | ₹1.17 Cr |
| Mar2024 | ₹0.98 Cr |
| Mar2023 | ₹0.95 Cr |
| Mar2022 | ₹0.67 Cr |
How is Contingent Liabilities of INDO US BIOTECH Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹2.91 Cr | 148.68 | |
| Mar2025 | ₹1.17 Cr | 19.86 | |
| Mar2024 | ₹0.98 Cr | 2.84 | |
| Mar2023 | ₹0.95 Cr | 42.64 | |
| Mar2022 | ₹0.67 Cr | - | |
Compare Contingent Liabilities of peers of INDO US BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDO US BIOTECH | ₹148.1 Cr | 22.8% | -3.4% | -40.5% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹3,414.5 Cr | -4.6% | -10.7% | -34.7% | Stock Analytics | |
| VENKYS (INDIA) | ₹2,112.0 Cr | -7.4% | -8.2% | 3.5% | Stock Analytics | |
| AVT NATURAL PRODUCTS | ₹1,337.5 Cr | -0.1% | -4.8% | 29% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹885.6 Cr | 1.7% | 0.2% | NA | Stock Analytics | |
| MANGALAM GLOBAL ENTERPRISE | ₹573.8 Cr | -4.3% | 8% | 16.3% | Stock Analytics | |
INDO US BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDO US BIOTECH | 22.8% |
-3.4% |
-40.5% |
| SENSEX | 1.8% |
2.3% |
-11.9% |
You may also like the below Video Courses